KPTI

Key Statistics

Latest News

Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special Meeting

MarketBeat 3 days ago

Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade

Zacks Feb 18, 2026

Analysts Have Made A Financial Statement On Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Annual Report

Simply Wall St. Feb 15, 2026

Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ...

GuruFocus.com Feb 12, 2026

Karyopharm Therapeutics Q4 Earnings Call Highlights

MarketBeat Feb 12, 2026

Community Sentiment

Sign in to vote

0 votes

Discussion (0)

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.